Alejandro Soto-Gutierrez, MD, PhD, is a physician-scientist whose career traces a clear path from discovery to translation in liver regenerative medicine. Trained in medicine at the University of Guadalajara, he completed a surgical internship before earning a PhD at Okayama University, Japan, where he helped reveal how liver non-parenchymal cells guide hepatocyte fate and maturation. His co-culture methods became widely adopted, leading to publications in top journals and early international prizes—signals of a career defined by originality and practical impact.

As a postdoctoral fellow at Harvard/Massachusetts General Hospital, he co-pioneered functional whole-organ liver engineering. That landmark work, together with an NIH-K99/R00, established the platform mindset he carried to the University of Pittsburgh: build human-relevant systems that both explain disease and point directly to therapies. Now Professor, Endowed Chair, and ViceChair leading the Division of Experimental Pathology, he advances “transcriptional therapy”—using mRNA to restore master regulators in failing human hepatocytes—reframing end-stage liver disease from a destination for transplantation to a condition amenable to programmable functional recovery.

His laboratory’s influence spans 120+ peer-reviewed papers, multiple patents, and two biotechnology companies: VonBaerWolff (autologous hepatocyte biofabrication) and Master Switch (transcriptional medicines progressing toward first-in-human studies). He is a driving force behind the Center for Transcriptional Medicine; directs the Human Liver Synthetic Biology Core within the NIH-funded Pittsburgh Liver Research Center; and leads NIH-supported resources that provide researchers nationwide with access to human liver cells.

An engaged educator and mentor, he served as Associate Director of the Cellular & Molecular Pathology graduate program, is Editor-in-Chief of Organogenesis and a member of the Hepatology Editorial Board, and is frequently invited for plenary and keynote lectures worldwide. Throughout, his theme is consistent: unite stem cell biology, organ engineering, and RNA therapeutics to restore liver function—and, ultimately, change how chronic organ failure is treated.